Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1

INTRODUCTION: The aim of this work is to assess the effect of upadacitinib versus adalimumab and placebo on patient-reported outcomes (PROs) in psoriatic arthritis (PsA) patients with inadequate responses to ≥ 1 non-biologic disease-modifying anti-rheumatic drugs (non-bDMARD-IR) in SELECT PsA-1. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Strand, Vibeke, Mease, Philip J., Soriano, Enrique R., Kishimoto, Mitsumasa, Salvarani, Carlo, Saffore, Christopher D., Zueger, Patrick, McDearmon-Blondell, Erin, Kato, Koji, Gladman, Dafna D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572257/
https://www.ncbi.nlm.nih.gov/pubmed/34636026
http://dx.doi.org/10.1007/s40744-021-00379-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572257/
https://www.ncbi.nlm.nih.gov/pubmed/34636026
http://dx.doi.org/10.1007/s40744-021-00379-9

Ejemplares similares